Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSH | P09668 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1135629 | 0.79 | CTSB (0.54) | CTSBCTSHALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL30810188 | 0.79 | CTSB (0.54) | CTSBCTSHALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL40986 | 0.79 | TDP1 (0.38) | ALDH1A1MAPTTSHRCYP3A4TDP1 | |
| SCHEMBL29518366 | 0.79 | TDP1 (0.38) | ALDH1A1MAPTTSHRCYP3A4TDP1 | |
| Methylamine SCHEMBL6028022 | 0.78 | TSHR (0.38) | CTSBCTSHALDH1A1MAPTRAB9A | |
| SCHEMBL136263 | 0.78 | CTSB (0.53) | CTSBCTSHALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL801581 | 0.78 | CTSB (0.62) | CTSBCTSHALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL30574931 | 0.78 | CTSB (0.53) | CTSBCTSHALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL30890730 | 0.78 | CTSB (0.53) | CTSBCTSHALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL9982714 | 0.78 | CTSB (0.53) | CTSBCTSHALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143108-B | 8-bromo-2-methylbenzofuran [2,3-b ] pyridine and synthetic method | 蒲城欧得新材料有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117143108-A | 8-bromo-2-methylbenzofuran [2,3-b ] pyridine and synthetic method | 蒲城欧得新材料有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-8735586-B2 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| US-8623521-B2 | Heterocyclic compound and organic light-emitting diode and flat display device including the heterocyclic compound | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-01-07 | — | — | US | disclosed |
| US-20120326134-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2012-12-27 | — | — | US | disclosed |
| EP-2173721-B1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-28 | — | — | EP | disclosed |
| EP-2173747-B1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | disclosed |
| EP-2173721-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | disclosed |
| EP-2173747-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | disclosed |
| CN-101687865-A | A regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI AVENTIS | 2010-03-31 | — | — | CN | disclosed |
| CN-101687815-A | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI AVENTIS | 2010-03-31 | — | — | CN | disclosed |
| WO-2009000413-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000412-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | AZI2, NISCH, UQCRB | CTSB 2088/4885CTSH 3570/4885ALDH1A1 97/4885 |
| US-20120326134-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | DDT, DRD1, HTR3D | CTSB 2730/4885CTSH 2472/4885ALDH1A1 24/4885 |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | AZI2, NIT2, NISCH | CTSB 3308/4885CTSH 3580/4885ALDH1A1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.